OR WAIT null SECS
January 11, 2021
The company plans to expand its global production capacity across six existing manufacturing facilities in Europe and the United States, as well as a new manufacturing facility in the US.
January 07, 2021
The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors.
The company plans to deliver initial doses by mid-2021, and Australia will have the option to purchase up to 10 million additional doses through the agreement.
Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.
January 06, 2021
The transaction will include operations located at different Novasep sites, including its Pompey, France site and sites in the United States, China, and India.
The collaboration will utilize ViGeneron’s novel engineered AAV capsids, vgAAV, to transduce retinal cells with intravitreal injections for an undisclosed target.
January 05, 2021
The new facility, to be located in Boston, MA, will contain experimental and analytical equipment for viral vector and advanced therapy process development and will expand the CDMO’s manufacturing capacity.
Angelini will obtain an exclusive license to commercialize Arvelle’s investigational anti-seizure medication, cenobamate, in the European Union and other countries in the European Economic Area.
January 04, 2021
The companies have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States.
Honeywell will use Sparta’s expertise to introduce new QMS solutions for life sciences to its customer base.